Gilead's oral drug beats placebo in mid-stage ulcerative colitis study
Gilead's emvistegrast, a daily tablet for ulcerative colitis, outperformed placebo on symptom relief and remission in a mid-stage trial, Reuters reported.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Gilead Sciences told Reuters on Monday that its investigational tablet, taken once a day, eased symptoms of a long-term bowel disorder in a larger share of patients than dummy treatment did in a mid-stage study. The compound, emvistegrast, was tested in adults with moderate-to-severe ulcerative colitis, a lasting disease marked by gut inflammation and sores.
After 12 weeks, 66% of people on the 200 mg dose showed symptom improvement versus 37% on placebo, hitting the study's primary target. Clinical remission was reached by 31% of treated patients compared with 8% on placebo. Side-effect rates were similar across both groups, and no serious adverse events were tied to the medication. Gilead intends to begin a late-stage monotherapy trial in 2027.
why it matters
The drug targets the α4β7 integrin pathway, a mechanism already validated in inflammatory bowel disease. BMO Capital Markets called the data an incremental positive for Gilead's inflammation franchise, though the results come from a mid-stage study and remain early.
market impact
Gilead (GILD): strong trial data supports interest in the company and its inflammation pipeline
tags
instruments
sources
- Gilead's pill succeeds in mid-stage bowel disease trial — Reuters, 19 October 2026 at 10:40 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗